CN113350404A - Specific Chinese medicinal composition preparation for treating and preventing cardiovascular and cerebrovascular diseases and application thereof - Google Patents
Specific Chinese medicinal composition preparation for treating and preventing cardiovascular and cerebrovascular diseases and application thereof Download PDFInfo
- Publication number
- CN113350404A CN113350404A CN202010972171.6A CN202010972171A CN113350404A CN 113350404 A CN113350404 A CN 113350404A CN 202010972171 A CN202010972171 A CN 202010972171A CN 113350404 A CN113350404 A CN 113350404A
- Authority
- CN
- China
- Prior art keywords
- medicine
- traditional chinese
- composition preparation
- cardiovascular
- cerebrovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 99
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 85
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 71
- 239000003814 drug Substances 0.000 claims abstract description 256
- 230000000694 effects Effects 0.000 claims abstract description 106
- 238000011282 treatment Methods 0.000 claims abstract description 79
- 229940079593 drug Drugs 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 38
- 239000008280 blood Substances 0.000 claims abstract description 31
- 210000004369 blood Anatomy 0.000 claims abstract description 31
- 244000178320 Vaccaria pyramidata Species 0.000 claims abstract description 28
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims abstract description 28
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 26
- 241001080798 Polygala tenuifolia Species 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 44
- 208000006011 Stroke Diseases 0.000 claims description 33
- 208000024891 symptom Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 26
- 239000006187 pill Substances 0.000 claims description 25
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 22
- 230000002490 cerebral effect Effects 0.000 claims description 20
- 230000036770 blood supply Effects 0.000 claims description 15
- 238000012545 processing Methods 0.000 claims description 14
- 241000208966 Polygala Species 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000002689 soil Substances 0.000 claims description 8
- 241000125175 Angelica Species 0.000 claims description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 7
- 241001233061 earthworms Species 0.000 claims description 6
- 230000001976 improved effect Effects 0.000 claims description 6
- 244000144730 Amygdalus persica Species 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 244000020518 Carthamus tinctorius Species 0.000 claims description 5
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 5
- 241000361919 Metaphire sieboldi Species 0.000 claims description 5
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 5
- 206010008118 cerebral infarction Diseases 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 4
- 241000243684 Lumbricus Species 0.000 claims description 4
- 244000170916 Paeonia officinalis Species 0.000 claims description 4
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 4
- 239000008561 buyang huanwu Substances 0.000 claims description 4
- 230000004069 differentiation Effects 0.000 claims description 4
- 230000000857 drug effect Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000003672 processing method Methods 0.000 claims description 4
- 238000005096 rolling process Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 210000004911 serous fluid Anatomy 0.000 claims description 3
- 239000008399 tap water Substances 0.000 claims description 3
- 235000020679 tap water Nutrition 0.000 claims description 3
- 229940107666 astragalus root Drugs 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims 4
- 241000382455 Angelica sinensis Species 0.000 claims 3
- 239000002994 raw material Substances 0.000 claims 2
- 210000000582 semen Anatomy 0.000 claims 2
- 210000000538 tail Anatomy 0.000 claims 2
- 241000510667 Conioselinum Species 0.000 claims 1
- 206010013911 Dysgeusia Diseases 0.000 claims 1
- 241000628997 Flos Species 0.000 claims 1
- 208000032023 Signs and Symptoms Diseases 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 43
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 description 32
- 230000017531 blood circulation Effects 0.000 description 24
- 210000004204 blood vessel Anatomy 0.000 description 23
- 238000011084 recovery Methods 0.000 description 21
- 230000001737 promoting effect Effects 0.000 description 15
- 206010008479 Chest Pain Diseases 0.000 description 11
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 11
- 244000132619 red sage Species 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 208000002173 dizziness Diseases 0.000 description 10
- 206010019233 Headaches Diseases 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 241001061264 Astragalus Species 0.000 description 6
- 235000006533 astragalus Nutrition 0.000 description 6
- 210000004233 talus Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 206010019468 Hemiplegia Diseases 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 241000213006 Angelica dahurica Species 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000005003 heart tissue Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229940126673 western medicines Drugs 0.000 description 3
- 239000009692 xuesetong Substances 0.000 description 3
- 206010008088 Cerebral artery embolism Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000008081 blood perfusion Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000010849 intracranial embolism Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 208000002040 neurosyphilis Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 208000023516 stroke disease Diseases 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 241001431291 Terana Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition preparation containing the prescription of traditional Chinese medicine for tonifying yang and returning five decoctions plus cowherb seed and polygala tenuifolia, and the preparation method of the pharmaceutical composition preparation is an overlapping effect pharmaceutical method, is efficient in concentration, simple and applicable, can improve a level in the aspects of prevention and treatment of cardiovascular and cerebrovascular diseases in traditional Chinese medicine, has a special curative effect, and belongs to the field of pharmacy; the special curative effect means that when the existing treatment method is invalid for patients with 1 stroke and sequelae, the medicinal composition preparation can reproduce curative effect and cure, reduce disability rate and improve cure rate; 2. when the life is reluctant to take care of oneself due to ineffective multi-drug treatment in the later stage of coronary heart disease, people can recover to normal people by taking the pharmaceutical composition preparation, and can participate in general physical labor; 3. can reduce blood viscosity and prevent recurrence and morbidity of cardiovascular and cerebrovascular diseases.
Description
The invention relates to a 'medicinal composition preparation' named Shenlingqiqiaohuoluotong capsule (pill, powder and tablet) containing traditional Chinese medicine ancient prescription for tonifying yang, five decoction, cowherb seed and polygala root, and the invention also relates to a medicinal composition preparation which has special curative effect on prevention and treatment of cardiovascular and cerebrovascular diseases in traditional Chinese medicine, and belongs to the field of pharmacy.
Background
Cardiovascular and cerebrovascular diseases and effects on human health (cardio-cerebral importance): cardiovascular and cerebrovascular diseases are generally referred to as cardiovascular and cerebrovascular diseases, including coronary heart disease, angina pectoris, apoplexy, cerebral ischemia, arteriosclerosis, hypertension, etc.; cardiovascular and cerebrovascular diseases become the most common diseases of middle-aged and elderly people, are serious diseases affecting human health, and are the first killer of chronic diseases; (Heart and brain are the most important vital organs of human body, the heart function is to promote the blood circulation of human body, to ensure the supply of whole body nutrition and necessary substances and to assist the metabolism of human body, the heart beat can not be affected at any moment; brain is the central organ of human body, generally leads the command of vital activities of viscera tissues of the whole body and the thinking activity of human, the function of brain can not be abnormal; the blood vessels supplying heart tissue and brain tissue play a vital role in maintaining the physiological activities and vital activities of heart and brain, therefore, the disease should not be affected, once the disease occurs, the normal function of heart or brain can be affected, even the life crisis occurs.)
The pathological mechanism of cardiovascular and cerebrovascular diseases: cardiovascular diseases and cerebrovascular diseases are homologous at the same place and have the same pathogenesis, so the cardiovascular diseases and the cerebrovascular diseases are collectively called as cardiovascular and cerebrovascular diseases, the main pathological changes are atherosclerosis, the atherosclerosis is easy to form plaques on the arterial wall, for example, the plaques are enlarged to cause vascular stenosis to cause insufficient blood supply of heart and brain tissues, and angina or headache and dizziness and other symptoms can occur; for example, the blood vessel is severely narrowed, and the blood vessel is suddenly contracted due to external factors (such as emergency or overexcitation) to prevent blood from running to cause myocardial infarction and sudden cardiac death; or cerebral infarction; plaque shedding can flow to thinner blood vessels along with blood, and can block the blood vessels to cause small blood vessel infarction and generate local symptoms; the dropping of large plaque can also cause the thinning of local vessel wall, and cerebral hemorrhage occurs when the blood pressure is suddenly increased, and the cerebral hemorrhage is an important factor for death caused by cerebrovascular diseases; because of the viscosity of blood and the stenosis of blood vessels, cerebral thrombosis (cerebral embolism) is easily caused by the slow blood flow in quiet or cold days; cerebral infarction, cerebral embolism, cerebral thrombosis, cerebral hemorrhage and clinical syndromes thereof are collectively called as stroke (or cerebral apoplexy), which easily injure human life or leave sequelae (causing human body to be disabled).
When the medicine is ineffective for patients suffering from coronary heart disease for a long time, the decline of heart function can be influenced by reasons of insufficient blood supply or myocardial strain, and the decline of the whole body function is further influenced to cause mental fatigue, weakness, hard physical strength and even life influence.
The traditional Chinese medicine considers that the diseases are closely related to blood stasis, qi stagnation and qi deficiency.
The current treatment situation, effect and existing problems of the cardiovascular and cerebrovascular diseases are as follows: the key point of the treatment of the cardiovascular and cerebrovascular diseases is to solve the problem of unobstructed blood flow in blood vessels, namely, the problems of blood viscosity of atherosclerosis, factors influencing blood flow, arterial plaque stenosis and the like; the problems of related organization function recovery and the like are also involved; (1) at present, western medicine has methods of diluting blood, expanding blood vessels, placing stents in blood vessels, performing vascular bypass surgery and combining Chinese patent medicines, and the like, and also solves some problems, particularly the state of an illness endangers life, and the stent placement or the vascular bypass surgery can be used for obvious effect at that time, so that a patient turns to be endangered; however, the abuse phenomenon of the existing heart stent also has certain influence on the human body without the upper stent; the stent is not only a foreign body, but also is easy to cause thrombosis; but also can not solve the problems of restenosis of blood vessels and recurrence of cardiovascular and cerebrovascular diseases; the reality that a lot of patients who are used as stents are used for stenting after a period of time or even are used for stenting for a plurality of times can be seen clinically; the phenomenon of vessel occlusion is easy to occur again when the bypass is made; because atherosclerosis is a systemic vascular disease, heart and cerebral vascular plaques do not necessarily occur at one position, even one blood vessel has multiple plaques, or multiple blood vessels have plaques; the method expands a blood vessel, other plaques are gradually increased and then are developed into new narrow parts, so that the fundamental problem cannot be solved, and the method is considered to be an excellent method for rescuing lives, but is a method for treating headache and foot pain, and treating symptoms and root causes but not treating the root causes; (2) patients suffering from coronary heart disease for a long time who take medicaments for treating cardiovascular and cerebrovascular diseases for a long time often have the phenomena that the medicaments are ineffective, the physique is rapidly declined, the life self-care is reluctant to be maintained, no medicament is available, and the life is almost waited for to end; (3) at present, the treatment of the stroke is also quite inappropriate, and although the treatment method is continuously abundant, the recovery of the blood supply and the function of brain tissues still seems to be ineffective; when short-term treatment in hospitals is ineffective, basically no medicine can be applied, and the medicine cannot be used, so that the lifelong disability is left, and therefore, the disability rate is high; at present, most of the cerebral apoplexy treatments in hospitals are discharged from the hospital from 8 days to 15 days; after discharge, the curative effect is very little even if the treatment is carried out by using various medicines and rehabilitation methods; (4) the prevention of cardiovascular and cerebrovascular diseases is not ideal, and smoking cessation and drinking limitation, reasonable diet, proper exercise, living saving, psychological balance and the like are often taught; patients with cardiovascular and cerebrovascular diseases take medicine for a long time for conditioning so as to prevent relapse; however, the morbidity and mortality of cardiovascular and cerebrovascular diseases only increase and do not decrease.
At present, the traditional Chinese medicine adopts methods of promoting blood circulation, removing blood stasis, dredging collaterals, tonifying qi, promoting qi circulation, promoting blood circulation and the like, can promote blood circulation and material exchange, dilute blood, regulate blood viscosity, promote metabolism, take away accumulated materials in blood vessels and blood vessel walls, increase blood freshness, promote normal conversion of the blood and the blood vessel walls, and is a better method for relieving and inhibiting atherosclerosis and increasing plaques; however, the purposes can be achieved only by taking decoction at present and continuously taking more than three months, so that patients can not take medicaments for treating cardiovascular and cerebrovascular diseases (without antihypertensive medicaments) for a long time; however, this method also has some problems, (1) dialectical treatment of traditional Chinese medicine is needed, and the above effects can be achieved by dialectical administration of a small number of traditional Chinese medicines; (2) decoction is troublesome; (3) even if the machine is used for decocting the medicines, the medicines are not convenient to take, because many people do not want to take the decoction, and particularly, people cannot insist on the decoction for 3 months continuously.
The Chinese patent medicine used in western medicine has poor effect of promoting blood circulation, removing blood stasis and dredging collaterals in normal times, but the common Chinese patent medicine is simple in preparation method, is prepared by directly processing Chinese herbal pieces into medicinal powder and then processing the medicinal powder into pills, powder, capsules, tablets and the like, or is prepared into liquid medicine and then adding auxiliary materials without medicinal functions into the liquid medicine to prepare granules, and has poor medicinal efficacy because of no concentration and the like; in addition, the Chinese patent medicine for promoting blood circulation and removing blood stasis focuses on promoting blood circulation, removing blood stasis and dredging collaterals, is not comprehensive in application to 'qi pushing and blood circulation' in the theory of traditional Chinese medicine, and lacks of driving force, so that the clinical curative effect is poor.
The data show that the clinical treatment scheme for acute cerebrovascular diseases is always lack, and the serious consequences of the cerebrovascular diseases bring heavy burden to the society and families. "
Disclosure of Invention
One of the purposes of the invention is to provide a new pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular diseases, which provides better choice for clinic; the second purpose is to provide a medicine for treating cardiovascular and cerebrovascular diseases with special curative effect; the third purpose is to provide a medicine which can effectively prevent the attack and the development of cardiovascular and cerebrovascular diseases; the fourth purpose is to reduce the morbidity and mortality of cardiovascular and cerebrovascular diseases; fifthly, the disability rate of the stroke is greatly reduced, and the cure rate is improved; the sixth purpose is to provide a simple and efficient method for using the traditional Chinese medicine.
The inventor discovers in research that (1) the traditional Chinese medicine has better effect of treating and preventing cardiovascular and cerebrovascular diseases, and the aim of reducing or preventing cardiovascular and cerebrovascular diseases can be achieved by dialectically using the traditional Chinese medicine decoction for treating the cardiovascular and cerebrovascular diseases for continuously taking for more than three months; (2) further research finds that the yang-tonifying and five-reducing decoction has better curative effect on treating cerebral apoplexy and can increase the cure chance; (3) the normal function of a patient with cerebral apoplexy sequelae is found to be recovered after two years; the detailed investigation and research show that the patient is the most different from others in that the components of the cowherb seed are added;the invention discloses a new discovery of treating cardiovascular and cerebrovascular diseases by using cowherb seed,the inventor combines the data with the clinical experience of the inventor, combines the yang tonifying and five decoction with the cowherb seed, the polygala root and other medicaments to form a prescription, and prepares the Chinese medicinal composition preparation by concentration processing, the clinical treatment effect of the apoplexy is good, and particularly when the hospital treatment is ineffective within one month after the stroke occurs, the reproducible curative effect of the Chinese medicinal composition preparation can be added or used to restore the normal function! And shows that the earlier the use, the better the effect; (4) continuous research finds that when various medicines for treating the coronary heart disease at the late stage are ineffective and patients reluctant to live for themselves, the body can be recovered to be normal by taking the medicine composition preparation; (5) research shows that the pharmaceutical composition preparation has good effect of preventing cardiovascular and cerebrovascular diseases, can eliminate symptoms, reduce blood viscosity, and can reduce the recurrence rate of cardiovascular and cerebrovascular diseases and the morbidity of cardiovascular and cerebrovascular diseases when being widely applied; (6) compared with decoction, the Chinese medicinal composition is easy to take and convenient to carry, and can be taken without differentiation of symptoms by a doctor.
The 'yang tonifying and five returning decoction' in the medicinal combined preparation is derived from 'medical and forestry improvement' of the Qing Dynasty Wang Qing ren, and consists of astragalus, angelica, ligusticum wallichii, red paeony root, peach kernel, safflower and earthworm, has the main functions of tonifying qi, activating blood and dredging collaterals, is a common prescription for treating diseases such as stroke, hemiplegia, facial distortion and the like, but generally has multiple purposes of decoction, and few people prepare Chinese patent medicines;
in the pharmaceutical composition preparation, "cowherb seed" has the functions of activating blood and stimulating menstrual flow, promoting lactation and reducing swelling; is a common medicine for postpartum hypogalactia, but the effect of activating blood and dredging channels and collaterals for treating cardiovascular and cerebrovascular diseases is not reported.
The polygala root in the medicinal composition preparation has the effects of calming heart and tranquilizing mind, eliminating phlegm and inducing resuscitation, and eliminating carbuncle and dissipating stagnation; is a common medicine for treating insomnia and amnesia, and has the effects of strengthening body and improving intelligence; but has not been reported in the aspect of treating cerebrovascular diseases by enlightening polygala;
preferably, the ratio of the astragalus root, the angelica, the szechuan lovage rhizome, the red paeony root, the earthworm, the peach seed, the safflower, the cowherb seed and the polygala root in the medicinal composition preparation is 5: 1: 0.6: 0.4: 1: 0.8, and the ratio of the traditional Chinese medicine decoction pieces for rolling the surface of the original medicine and decocting the liquid medicine can be basically the same;
the dosage of the astragalus in the medicinal composition preparation is more than five times of that of other medicaments, so that the treatment method of 'qi pushing and blood circulation' mainly tonifying qi is fully embodied; the ancient Yang tonifying and Wu returning decoction is a prescription for mainly treating stroke hemiplegia, wherein four and two astragalus roots are used as main medicines in each prescription, which is equivalent to 125 g of the existing medicine, 3 to 6 g of other medicines are used, and the dosage difference is very obvious, so that firstly, the stroke is mainly caused by qi deficiency, and secondly, the importance of supplementing vital qi to assist the promotion of blood circulation is explained; the theory of traditional Chinese medicine considers that 'qi pushes away blood to move, qi moves blood to move, and qi stagnation and blood stagnation' are caused, so that when blood stasis is treated: firstly, the blood-activating medicine and the qi-moving medicine can assist the blood circulation, and secondly, the blood-activating medicine and the qi-tonifying medicine can assist the blood circulation; the ancient people used qi tonics for treating stroke in an excessive amount, which proves that the ancient people pay attention to deficiency of healthy qi of the patients with stroke, realizes the great significance that the blood can be pushed to run only by supplementing healthy qi, and has great difference from the existing Chinese patent medicine for promoting blood circulation to remove blood stasis, namely promoting blood circulation to remove blood stasis and dredging collaterals; the existing Chinese patent medicines for promoting blood circulation and removing blood stasis basically do not have the mode of reusing qi tonifying medicines; therefore, the deficiency of qi-tonifying or no use of qi-tonifying medicine at all is one of the important reasons for the poor action of the Chinese patent medicine for promoting blood circulation and removing blood stasis; the characteristic of the medicinal composition preparation is that a great amount of tonifying qi is utilized to drive blood to move.
Preferably, the Chinese herbal pieces of astragalus, angelica, ligusticum wallichii, radix paeoniae rubra, earthworm, peach kernel, safflower, cowherb seed and polygala tenuifolia in the medicinal composition preparation are selected to be more than the grade.
Preferably, the traditional Chinese medicine composition in the pharmaceutical composition preparation is characterized in that the astragalus in the traditional Chinese medicine composition is raw astragalus.
Preferably, the Chinese medicinal composition in the medicinal composition preparation is characterized in that the Chinese angelica in the Chinese medicinal composition is angelica tails, and the Chinese angelica can be replaced by whole Chinese angelica without the angelica tails.
Preferably, the lumbricus in the pharmaceutical composition of the present invention is a soil-removed lumbricus, and most of the lumbricus with slightly soil on both ends of the soil removed may be used if the soil is not completely removed, but the earthworms with too much soil cannot be used.
Preferably, the traditional Chinese medicine composition in the pharmaceutical composition preparation is characterized in that the dosage of the cowherb seed in the traditional Chinese medicine composition is half of the dosage of raw cowherb seed and half of the dosage of the parched cowherb seed, and if no raw cowherb seed exists, the cowherb seed can be completely replaced by the dosage of the parched cowherb seed.
Preferably, the traditional Chinese medicine composition in the pharmaceutical composition preparation is characterized in that the polygala root in the traditional Chinese medicine composition must be core-pulling polygala root.
The optimal selection of the medicine is important, the quality of the medicine is closely related to the curative effect, and the better curative effect of the preparation can be ensured only by selecting the medicine according to the requirement.
Preferably, the processing method of the pharmaceutical composition preparation adopts an overlapping efficacy concentration pharmaceutical method, and is characterized by comprising the following steps:
(1) preparing the raw medicine powder: selecting medicinal decoction pieces according to the optimal proportion of 11, crushing the medicinal decoction pieces selected according to the optimal medicinal standard of 12-17, and sieving to obtain fine medicinal powder as the original medicinal powder (with the first medicinal effect);
(2) decocting to obtain a liquid medicine: selecting decoction pieces of traditional Chinese medicine according to the optimal proportion of 11, selecting decoction pieces of traditional Chinese medicine according to the optimal proportion of 12-17, adding water into the decoction pieces of traditional Chinese medicine g and tap water ml according to the proportion of 1: 1.5 for half an hour, decocting at 100-125 ℃ for 50-60 minutes, pouring out liquid medicine, removing residues and filtering; adding water until the water is 1cm higher than the decoction dregs, decocting at 100-125 ℃ for 50-60 minutes, pouring out the liquid medicine, removing the residues and filtering; the liquid medicines decocted for four times are mixed for standby.
(3) Concentration processing: decocting the liquid medicine obtained in the step (2) at the temperature of 70-125 ℃ for about 10-12 hours to obtain 50% concentrated serous fluid (the second drug effect).
(4) Molding and drying: adding the concentrated serous liquid medicine decocted in the step (3) into the original medicine powder according to the proportion of about 2: 1, uniformly stirring (overlapping medicine effect), processing into small blocks according to dryness and humidity, and airing for later use.
(5) And (3) secondary processing: pulverizing the dried medicine in the step (4), rolling into fine powder, sieving with a 100-mesh sieve to obtain pure fine powder for later use,
(6) and (3) final forming: and (4) preparing the pure fine powder processed in the step (5) into pills, powder, tablets and capsules according to the requirements of patients.
The pharmaceutical composition preparation of the invention is characterized in that:
(1) the medicine curative effect is enhanced by a pharmaceutical method with two overlapped medicine effects, the medicine powder is rolled by traditional Chinese medicine decoction pieces for standby, the effect equivalent to that of a common Chinese patent medicine is taken as the first medicine effect, the same traditional Chinese medicine decoction pieces are decocted and concentrated, the effective component is extracted to be the second medicine effect, the standby medicine powder in the first medicine effect is added into the concentrated medicine liquid with the same second medicine effect and is uniformly stirred, and the curative effect is increased by the two-time medicine effect overlapping.
(2) The cowherb seed in the pharmaceutical composition preparation has good curative effects of promoting blood circulation and removing obstruction in channels, and is helpful for recovering the function of the disabled histiocyte;
(3) the combination of the resuscitation effect of the polygala has better effect on the recovery of the language of a patient;
(4) the medicinal composition preparation is prepared by processing and concentrating yang-tonifying five-component decoction, cowherb seed and polygala tenuifolia, so that various components of various medicaments are decomposed and combined in the decocting process to generate better curative effect;
(5) the remarkable curative effect is as follows:
(a) before the pharmaceutical composition preparation of the invention appears, all patients with cerebral apoplexy who are not effective for hospital treatment generally have no or very little curative effect no matter what drugs and methods are used for treatment after hospital discharge, but the pharmaceutical effect is good, especially the effect of the patients within one month after illness is better, in short time after illness, the curative effect is better;
(b) for patients suffering from coronary heart disease for a long time, the physical condition can decline rapidly and threaten death when the medicine is not available due to long-term taking or failure of changing the medicine for many times; but the body can gradually recover normal functions after the medicinal composition preparation is used;
(c) for patients suffering from suspected angina pectoris caused by chronic coronary heart disease or suffering from cerebrovascular disease with headache and dizziness similar to cerebral blood supply insufficiency, the patient is suspected to have the possibility of relapse of the disease progress, and the possibility of relapse is prevented because the blood supply improvement symptom disappears by taking the pharmaceutical composition preparation;
(d) for patients who do not suffer from cardiovascular and cerebrovascular diseases, have headache and dizziness similar to angina pectoris or cerebral ischemia, are diagnosed by doctor as having cardiovascular and cerebrovascular ischemia and possibly develop into cardiovascular and cerebrovascular diseases, the symptoms can be eliminated and the cardiovascular and cerebrovascular diseases can be prevented by taking the pharmaceutical composition preparation.
After the inventor prepares the pharmaceutical composition preparation, the following studies were made to confirm the therapeutic effect of the drug:
(1) firstly, a patient with general paralysis who has no effect after using a plurality of medicines and methods about one year after a disease is tried to be treated, the life self-care function is gradually recovered after using the pharmaceutical composition preparation for treating the general paralysis for five and six months, and at least, the pharmaceutical composition preparation can be considered to be possibly effective for the patient about 1 year after the disease;
(2) the effect of early-stage patients who are tried to be used in hospitals for treating ineffective stroke diseases is very good, the first trial is that patients who do not take effect in ten days of hospital treatment after stroke diseases take the pharmaceutical composition preparation, the pharmaceutical composition preparation takes effect in 11 days, can get out of bed for activity in 12 days, and are discharged out of hospital in 13 days; the second trial example is that a patient who is invalid for one month is treated by western medicine methods in a hospital after stroke, the patient is discharged for treatment after the 8 th day of curative effect after using the pharmaceutical composition preparation, and the body is gradually improved to be completely recovered after the patient is discharged and continuously uses the pharmaceutical composition preparation; according to the conjecture of the curative effects of the two cases, the pharmaceutical combination preparation has better treatment effect on the patients with the cerebral apoplexy who are ineffectual in hospital treatment within one month or shorter; should be more recoverable in the short term, easier;
these two cases show patients who are recoverable for patients who are not eligible for hospital treatment, so the pharmaceutical combination should have the following effects:
(a) the pharmaceutical composition preparation has the functions of recovering blood perfusion in brain injury areas, relieving nerve cell injury, saving the recovery function of cells in ischemic penumbra areas, thrombolysis, anticoagulation and the like.
(b) It may have the function of neuroprotective factor and can promote the survival, growth and differentiation of neuron. Promoting the development of neurons, activating the activity of enzyme, repairing the neurons, and playing a role in regulating neurotransmitter, synaptic plasticity and the like;
(c) but also has positive regulation effect on body fluid and other systems. Thus gradually restoring the physiological functions of nerves, body fluid, cells and other systems;
(3) the medicine is used for patients suffering from coronary heart disease for a long time and losing curative effect by using all medicines, and the life of the patients is reluctant to take care of the patient due to the attenuation of the whole body function: according to 0003, cardiovascular diseases and cerebrovascular diseases have the same homology and pathogenesis, so that the specific medicine for treating the cerebrovascular diseases is considered to be effective for patients with coronary heart disease, and the specific medicine is just introduced to patients in medical institutions who have serious illness and many medicines are ineffective, so that the specific medicine is just used for the first test by using the pharmaceutical composition preparation;
(a) the first patient on trial just worried life self-care to endanger life because the body of the patient suffered from coronary heart disease is weak for a long time; the medicine composition preparation of the invention is like a regular person in three months, and can participate in general physical labor;
(b) the second patient on trial suffers from diabetes and coronary heart disease for a long time, can be treated by various high-quality medicines at home and abroad, but suddenly feels tiredness and fatigue to be gradually aggravated after more than 20 years, the medical experts adjust the medicines for multiple times, the physique still slides downwards, the body of the medicinal composition preparation is gradually recovered to be normal after three months on trial, the medicinal composition preparation is stopped taking continuously for five years, the body is very good after the age of 85 years, the cold is obviously reduced in recent years, and the patient often climbs mountains;
at present, patients suffering from coronary heart disease for a long time have individual difference due to too long medicine taking time, and some patients lose efficacy of medicines and almost see the patients to die; however, after the medicine composition preparation is taken, the patients can be enabled to be like a normal person; the pharmaceutical composition preparation can not only recover the blood supply of the heart and the function of heart tissues, but also recover the physical ability and regulate the functions of a plurality of systems of the body.
The following studies were made again based on the above therapeutic effects:
(1) the study on the population from one month to half a year after cerebrovascular disease shows that the contrast can recover self-care or recover basic function, but the population actually taken into the treatment group is basically two and a half months to four and a half months, so the control group also selects patients from two and a half months to four and a half months; the treatment group is treated by the pharmaceutical composition preparation, and the control group is treated by massage rehabilitation therapy; after 3-5 months of treatment, the patient can recover the patient to eat, relieve the bowels, write or speak clearly and the like by utilizing the original hemiplegic limbs as basic recovery, wherein the basic recovery comprises the recovery of one function (for example, the original writing can only write a single character, can not be connected into sentences, and can be connected into sentences at present). 38 cases of the treatment group, 21 cases of the basic self-care recovery, the basic recovery rate is 55.3 percent, and 41 cases of the control group, the basic recovery rate is 7.3 percent, and the statistical P is less than 0.05 and less than 0.01;
(2) part of patients with cardiovascular and cerebrovascular diseases gradually have frequent chest distress and chest pain or dizziness and headache similar to blood supply insufficiency symptoms during long-term taking, and because the patients have already diagnosed the cardiovascular and cerebrovascular diseases, most of the patients take the medicines for treating the cardiovascular and cerebrovascular diseases under the guidance of doctors, and the medicines are Chinese patent medicines and western medicines, particularly the Chinese patent medicines taken are different; the disease condition is generally aggravated when the disease occurs, and the disease condition is easy to relapse; at the moment, the Chinese patent medicines are generally temporarily taken by quick-acting heart-saving pills or salvia miltiorrhiza dropping pills, and the number of patients who take the salvia miltiorrhiza dropping pills continuously for a long time is small, but some patients take the salvia miltiorrhiza dropping pills continuously for one year; therefore, the therapeutic effect of the salvia miltiorrhiza dropping pill is compared with that of the medicinal composition preparation; the treatment group uses the pharmaceutical composition preparation, and the control group uses the salvia miltiorrhiza dripping pill; the two medicines are required to be taken for 100 days and stopped; during taking the medicine composition preparation of the invention by a treatment group and after stopping taking the medicine for 100 days, other medicines (without antihypertensive medicines) for treating cardiovascular and cerebrovascular diseases are stopped, the original medicines cannot be stopped during taking the salvia miltiorrhiza dripping pills by a control group, and after taking the salvia miltiorrhiza dripping pills for 100 days, other medicines are continuously taken; observing the curative effect of the two medicines after stopping taking the medicines for 3 months, and then basically curing the medicines without symptoms, wherein 33 patients are treated in a treatment group and 26 patients are basically cured, 12 patients are treated in a control group and 2 patients are basically cured, and the statistical P is less than 0.05 and less than 0.01;
(3) in addition, more patients are not diagnosed with the cardiovascular and cerebrovascular diseases, some patients detect insufficient blood supply of the cardiovascular and cerebrovascular blood vessels, and more detection is not abnormal, but the patients are generally diagnosed with the insufficient blood supply of the cardiovascular and cerebrovascular blood vessels by doctors and are considered as the early-stage manifestation of the cardiovascular and cerebrovascular diseases because chest pain and stuffiness or chest pain involving the back, dizziness and dizziness frequently occur, and the cardiovascular and cerebrovascular diseases are possibly developed; in such cases the pharmaceutical combination formulation of the present invention is therapeutically effective and is studied as follows: the treatment group was treated with the pharmaceutical combination preparation of the present invention; the control group used Xuesaitong; the medicine taking time of the treatment group and the control group is 100 days; after stopping taking the medicine, observing for 3 months, the asymptomatic reoccurrence is clinical cure, the patients cured clinically are not easy to suffer from the cardiovascular and cerebrovascular diseases, 46 patients are selected from the treatment group, 38 patients are cured clinically, 21 patients are treated in the control group, 9 patients are cured clinically, and the statistics P is less than 0.05.
According to the results of 41(1), if the pharmaceutical composition preparation of the invention is applied to the population in 4 and a half months after illness in large quantity, the self-care ability of the disabled patients can be greatly improved, the social and family pressure can be reduced, and the effect of 37(2) is combined to be applied to the population, so that the disability rate can be greatly reduced, and the cure rate can be improved.
According to 41(2), if the medicine can be widely applied to people suffering from cardiovascular and cerebrovascular diseases for a long time, the recurrence rate of the cardiovascular and cerebrovascular diseases is obviously reduced; the combination of the effects of the components 38 and 3 has the advantages that the death rate of chronic patients with coronary heart disease can be greatly reduced by widely applying the components to people with advanced coronary heart disease, and more patients with coronary heart disease who are dying can be regenerated;
the effects according to 41(3) can be widely applied to people with primary cardiovascular and cerebrovascular diseases; can greatly reduce the incidence of cardiovascular and cerebrovascular diseases.
Detailed Description
The following examples further illustrate the pharmaceutical combination preparations of the present invention, but are not intended to limit the technical solutions and effects of the present invention.
Example 1: the formation of the pharmaceutical composition preparation of the invention is inspired by the fact that all normal cases suddenly recover after two years of cerebrovascular disease sequelae, the medication, life and activity habits of patients are inquired in detail, according to the comparison between all the introduced conditions of the patients and the traditional Chinese and western medicines taken by the similar patients at that time, the invention preferably selects the things which are considered by the inventor to be different from others at that time but are related to the treatment of the disease as research contents, and then finds out the medicine and the life and activity contents which are most likely to have main effects by combining with the relevant data of medical theory investigation, and finally makes a judgment; the Chinese medicine of the cowherb seed is the most special and relevant in the medicine, and the cowherb seed is a Chinese medicine for promoting blood circulation and removing obstruction in channels, has reasonable image and science, and is considered as an effective main component of the patient.
The key medicines are determined, and then the prescription and the medicines to be matched are determined, because the content to be researched is to treat the cerebral apoplexy (cerebral apoplexy) and the sequelae thereof, the inventor has made a research on the disease, and selects ' Buyang Huanwu decoction ' and polygala root and cowherb seed ' by combining the ancient prescription and the own clinical experience;
the 'Buyang Huanwu Tang' is originated from 'Yi Lin correction' of the Wang Qing ren of the Qing Dynasty, is a common prescription for tonifying qi, activating blood circulation, dredging collaterals and treating apoplexy, hemiplegia, facial distortion and other symptoms, and has good effect in clinically treating cerebral apoplexy; the polygala root has the resuscitation effect, so that the mind can be conscious, the language can be gradually restored, and the like; the functions of the cowherb seed for promoting blood circulation and removing obstruction in channels are combined, so that qi and blood circulation of cerebral apoplexy can be promoted, and the channels and collaterals are dredged, so that the body can gradually recover the functions;
the medicinal composition preparation has the following effects in Western medicine: has the effects of restoring blood perfusion in brain injury area, relieving nerve cell injury, saving cells in ischemic penumbra area, thrombolysis, anticoagulation, etc.; has the function of neuroprotective factor, can promote the survival, growth and differentiation of neurons, promote the development of neurons, activate the activity of enzyme, repair neurons, play the functions of regulating neurotransmitter, synaptic plasticity and the like; but also has positive regulation effect on body fluid and other systems. Thus gradually recovering the physiological functions of nerves, body fluid, cells and other multiple systems;
in the past, the use of the medicines in the prescriptions uses decoction, but the decoction is inconvenient to use, doctors need to find the prescription frequently, the medicines need to be decocted, the taste of the decoction is not good, so the Chinese patent medicine is prepared, and the curative effect is ensured, so the medicine adoptsConcentrated pharmaceutical method with overlapped drug effects。
Example 2: preferably, the method for processing the pharmaceutical combination preparation with overlapping drug effects by concentration is characterized in that,
firstly, 7375 g of Chinese medicinal decoction pieces are selected and uniformly mixed, washed by clear water once, dried in the air, 2935 g of the mixture is rolled into medicinal powder for later use, which is called as the original medicinal powder, the curative effect of the medicine is equal to the effect of common Chinese patent medicines at the moment, namely the first curative effect,
secondly, 4420 g of selected dried Chinese medicinal decoction pieces from 51I are soaked in 6500ml of water for half an hour for decoction and concentration, the extracted active ingredient is the second Chinese medicinal efficacy component, 1400 g of the original medicinal powder from 51I are weighed and added into the concentrated liquid medicine, the mixture is uniformly stirred, processed and dried for later use, the efficacy of the medicinal powder is the efficacy of the concentrated liquid medicine, and the efficacy of two times of the same efficacy is equal to that of the overlapped efficacy, so that the efficacy is increased. The specific manufacturing method comprises the following steps:
example 3: the processing method of the pharmaceutical composition preparation comprises the following steps:
(1) preparing the raw medicine powder: selecting 7375 g of traditional Chinese medicine decoction pieces according to the preferable medicine standard of 12-17 according to the preferable proportion of 11, uniformly stirring, washing once by using clear water, and airing; 2935 g of the dried medicinal decoction pieces are taken and crushed, and the crushed medicinal decoction pieces are sieved by a sieve with 80 to 100 meshes, and the obtained medicinal fine powder is reserved; in order to ensure that the weight of the original medicine powder and the concentrated liquid medicine is more accurate, 2950 g of medicinal decoction pieces and 4425 g of medicinal decoction pieces can be selected according to the medicine selection requirement, the medicinal decoction pieces are respectively and uniformly stirred, the medicinal decoction pieces are respectively washed and dried, 2950 g of dried medicinal decoction pieces are crushed and sieved by a sieve of 80-100 meshes, and the obtained fine medicine powder is used as the original medicine powder.
(2) Decocting to obtain a liquid medicine: selecting 4425 g of dried Chinese medicinal decoction pieces in 53(1), adding 6500ml of tap water, soaking for half an hour, decocting at 100-125 ℃ for 50-60 minutes until about 3000ml of liquid medicine is left, pouring out, removing residues and filtering; adding water until the water is 1cm higher than the decoction dregs, decocting at 100-125 ℃ for 50-60 minutes, pouring out the liquid medicine, removing the residues and filtering; mixing the decoction obtained by decocting for four times for later use; in summer, the liquid medicine can be concentrated after being poured out twice, two furnaces are needed, and the liquid medicine is concentrated while being decocted so as to prevent the liquid medicine from deteriorating.
(3) Concentration processing: decocting the liquid medicine obtained in the step 53 and the step 2 at the temperature of 70-125 ℃ (boiling with strong fire and decocting with slow fire), and decocting for about 10-15 hours to obtain 50% concentrated slurry.
(4) Molding and drying: adding 1400 g of original medicine powder into concentrated serous liquid medicine decocted in step 54(3), uniformly stirring, processing into small blocks of about 0.5 x 0.8cm according to dryness and humidity, and airing for later use.
(5) And (3) secondary processing: the 55(4) dried medicine is crushed, milled into fine powder, sieved by a 100-mesh sieve into pure fine powder for standby,
(6) and (3) final forming: the pure fine powder processed by the step 56 and the step 5 is prepared into pills, powder, tablets and capsules according to the requirements of patients. The preparation process of the medicinal composition preparation is completed by preparing pills, powder, tablets and capsules,
example 4: initial trial of the pharmaceutical composition formulation of the invention:
(1) the first patient to try the pharmaceutical combination formulation of the present invention; example 1: yang xx, male, 71 years old, is a patient who starts to take the pharmaceutical composition preparation in the last year after illness, originally is more than 3 years of right-side hemiplegia, and the inventor has requested that the pharmaceutical composition is prepared for the pharmaceutical treatment, but no effective medicine can be prepared (the inventor has basically failed to research on cerebrovascular disease sequelae); after the cerebral apoplexy of the inventor occurs again, the inventor encounters a patient who is cured suddenly after two years, and develops the medicine combination prescription for the inventor; the left paralysis is caused by the disease of the patient, so the whole body can not move, the patient can still feel soft like noodles and can not move when being treated by various medicines and methods for more than 11 months in a plurality of hospitals, and the speaking is difficult to hear; in order to be convenient and efficient to take, the inventor concentrates and processes the medicine prescription into capsules; after 11 patients half a month begin to take the medicinal composition preparation, the patients feel that the bodies of the patients are stronger than the original bodies after taking the medicinal composition preparation for one month, about two months are gradually put up, the speaking is gradually clear, after taking the medicinal composition preparation for 4 months, the left side function is recovered to the self-care of life, the speaking is similar to that of a regular person, and the patients can eat the medicinal composition preparation by the left hands more proficiently. This example shows that patients who have been treated with multiple drugs and methods in multiple hospitals and who have not seen a little effect in the last year, recover self-care function in life about half a year after using the pharmaceutical combination preparation of the present invention! The therapeutic effect in this case suggests that the pharmaceutical combination preparation of the present invention is expected to treat patients about one year after the disease.
(2) The most promising two patients for the pharmaceutical combination formulation of the present invention; example (c): 2: 66 years old man with cerebral blood tied to a hospital in a certain city, and ten-day paraplegia without any progress, after the medicine is added, fingers can move on the eleventh day and get out of bed for activity on the twelfth day! Let the inventor then create a large heap "? Is the effect of the drug? Is the coincidence of the original medicine? Or the combination of the original drug and the original drug? In a word, the patient is discharged and returned home on the thirteenth day; after going home, only take the medicine and hypotensor.
Example 3: xxxx women aged 58 years old, suffered from apoplexy and fell into a hospital (a third hospital) in a certain city, an organization specialist treats the hemiplegia for one month by using various methods of traditional Chinese and western medicine, the hemiparalysis does not half-way improve, the medicine is taken after the disease starts to be taken at 30 days, fingers can move after the medicine is taken at 8 days, the patient is discharged from the hospital and is taken with the medicine for treatment, the improvement of the body is gradually healed one day, the medicine is taken for one year, and the exercise is continued! The patients can be cured after one month, which shows that the medicine has good curative effect! As mentioned above, as long as the patients who are not treated effectively in the hospital are discharged from the hospital for 8 days or half a month, the treatment effect is very little by using any medicine or method; however, the patients in the embodiment can still be cured after taking the medicine for one month in the hospital treatment, which shows that the curative effect of the medicine for the patients in the embodiment is supernormal.
Through the 3 cases, the pharmaceutical composition preparation can be basically considered to have a curative effect that all similar medicines can not reach completely on the cerebral apoplexy (cerebral apoplexy); by re-inferring the efficacy of example 2 from examples 1 and 3, the drug plays an important role in this case at least, or the drug is better for a short period of time (e.g., within 15 or 10 days after disease)! Providing hope for us; if the medicinal composition preparation is taken particularly at the early stage of easy recovery, most patients can use the medicinal composition preparation and can achieve the effect, and many patients can be recovered.
(3) The medicinal composition preparation is used for patients with coronary heart disease, who take medicines for a long time and have gradual failure and rapid decline of physique:
according to the theory that coronary heart disease and cerebrovascular disease are homologous and the pathogenesis is the same, the medicine for treating cerebrovascular disease is effective for treating coronary heart disease;
example 1: x x, female, 61 years old, 3 years after thyroidectomy with coronary heart disease, because the disease of coronary heart disease is gradually aggravated, the patient can not participate in all labor and activities, and is reluctant to live and take care of oneself; the introduction starts to try out the medicinal composition preparation, and after the medicinal composition preparation is taken for a half month, the self-induction physical condition is obviously lighter than the original physical condition; after taking the medicine for 100 days, the medicine is similar to a common person and can do various housework and general work.
Example 2: era x x, male, age 78, retirement; the diabetes mellitus is suffered for 25 years before the medicine is used, the insulin is used for treating the diabetes mellitus for 12 years, and two stents are placed in a heart blood vessel before 9 years due to the combination of the diabetes mellitus with coronary heart disease and myocardial infarction; the medicine is familiar with a plurality of related experts in the national hospitals of northern university, so the most advanced medicine in the world can be tried out, and the physical condition is good for many years; however, in 2013, the physical condition tends to decline, the spirit is tired, the miscellaneous diseases are clustered, and the curative effect is poor due to the fact that experts adjust medicines for multiple times; the patient does not believe the traditional Chinese medicine, but wants to try to treat the disease by using the medicinal composition preparation because the effect of the traditional Chinese medicine is good; after the medicinal composition preparation is taken, the body is improved in half a month, and the body is recovered to be normal after 100 days, and the patient often goes to mountain climbing for playing. After the medicine is continuously taken for 5 years, the medicine is stopped for one and a half years, the people are 85 years old, the body is good, and the cold is rarely suffered until now during the medicine taking period. Obviously improves the physical condition and increases the immunity of the body.
In cases according to 61(1), many patients are ill for more than one year, but the initial onset of action is long or the patients lose confidence, and few patients who are willing to cooperate with the treatment are present; patients according to 62(2), 63(3) are the best subjects for the study of the pharmaceutical combination preparation, but the patients are difficult to find, so the two types of patients are ready to be studied at a later opportunity;
study of two to four and a half months of population after stroke:
setting a treatment group and a control group, wherein the treatment group is treated by using the pharmaceutical composition preparation, the control group is treated by using massage rehabilitation therapy, patients with the ages of 35-65 years are selected, men and women are not distinguished, treatment methods are taught to the patients according to the diagnosis sequence, treatment methods (which are divided into different groups) are freely selected, and the condition that the contrast ratio can recover self-care or recover basic functions is observed; after 3-5 months of treatment, the patient can recover the self-eating, the urination and the defecation, the writing or the speaking is obvious and clear and the like by utilizing the original hemiplegic limbs as basic self-care or basic recovery, wherein the recovery comprises a function (for example, the original writing can only write a single character, can not be connected into sentences, can be connected into sentences at present); treatment groups were selected from 38 cases (not 59(1) and 60 (2)); 41 cases of the control group are selected; from the recovery process, the number of effective people started is faster than that of the treatment group, but the effect of the control group is worse and worse along with the prolonging of the time, particularly, the recovery degree to self-care is difficult, and finally, 38 cases of the treatment group, 21 cases of the basic self-care recovery, the basic recovery rate is 55.3 percent, 41 cases of the control group, the basic recovery rate is 3 cases of the basic self-care recovery, the basic recovery rate is 7.3 percent, see the table (1) and the table (2)
TABLE (1) therapeutic effect observation table
The clinical significance of the effect and the obvious effect is not great, and the clinical significance is only achieved when the function is basically recovered, so that the meaningful treatment is only carried out on patients
TABLE (2) statistics of basic function recovery
p is less than 0.05 and less than 0.01, which shows that the treatment group has very significant effect
In addition, for patients who take cardiovascular and cerebrovascular diseases for a long time and have symptoms and patients who are not diagnosed as having chest pain and discomfort or headache and dizziness of the cardiovascular and cerebrovascular diseases, particularly patients who have no effect on western medicine treatment can generally find traditional Chinese medicine treatment, and the two groups of people are also people researched by the inventor;
the study on the crowd who reappear chest distress and chest pain or dizziness and headache symptoms during long-term taking of the medicine for treating the cardiovascular and cerebrovascular diseases:
the group of people is patients who have already confirmed diagnosis of cardiovascular and cerebrovascular diseases, so most of the patients take traditional Chinese and western medicines for treating the cardiovascular and cerebrovascular diseases under the guidance of doctors, and if symptoms occur again, the disease condition is aggravated, and the diseases are easy to relapse; at this time, the Chinese patent medicine quick-acting heart-saving pill or the red sage root dripping pill is usually selected for temporary administration, and is less frequently taken continuously for a long time; otherwise, the medicine is a western medicine for expanding blood vessels, and the curative effect is generally poor by using other Chinese patent medicines; the pharmaceutical composition preparation of the present invention is effective for patients with coronary atherosclerosis because it has a therapeutic effect on such patients;
the research project sets a treatment group and a control group, the treatment group is treated by the pharmaceutical composition preparation of the invention, 5 granules are taken once, and the treatment is taken twice a day; the control group uses Saviae Miltiorrhizae radix dripping pill, 8 granules once, once a day; patients who need to take the pharmaceutical composition preparation of the invention in the treatment group are required to stop taking all the medicines for treating cardiovascular and cerebrovascular diseases (without antihypertensive medicines, but unwilling to stop taking medicines); the control group can not stop using all the original medicines during taking the red sage root dripping pills; the medicine taking time of the treatment group and the control group is 100 days; whether the symptoms relapse or not is mainly observed after 3 months after the medicine is stopped, and the symptoms which do not relapse are basically cured; patients with ages between 35 and 65 years, regardless of male and female, were instructed on the treatment method according to the order of arrival, with freedom to choose what method (divided into different groups) to treat; 33 patients were selected for the treatment group, 12 patients were selected for the control group, and the treatment conditions are shown in the following table; according to the temporary symptom elimination condition, the salvia miltiorrhiza dropping pills in the control group are obviously better than those in the treatment group, the salvia miltiorrhiza dropping pills can show symptom elimination after the administration time is short, but the salvia miltiorrhiza dropping pills are easy to relapse after the administration is stopped; the treatment group also has quick response, but generally has more effect after about one week, some symptoms disappear completely even after 2-3 weeks, but the symptoms are not easy to relapse after the medicine is stopped. The clinical significance is achieved only when the symptoms are not recurrent after the medicine is stopped, so that the cardiovascular and cerebrovascular diseases are not easy to recur; the list is as follows:
statistical table of treatment conditions of pharmaceutical composition preparation (treatment group) and salvia miltiorrhiza dropping pill (control group) of the invention
p is less than 0.05 and less than 0.01, which shows that the treatment group has very significant effect
The study on patients who have chest pain discomfort or headache and dizziness due to cardiovascular and cerebrovascular diseases without diagnosis: many patients are not diagnosed with cardiovascular and cerebrovascular diseases, some patients detect insufficient blood supply of cardiovascular and cerebrovascular blood vessels, and many patients do not detect abnormal blood supply, but most patients are diagnosed with insufficient blood supply of cardiovascular and cerebrovascular blood vessels by doctors because chest distress and chest pain or chest pain involving the back, dizziness, headache and other symptoms often occur, the patients are considered as the early-stage manifestation of the cardiovascular and cerebrovascular diseases and are likely to develop the cardiovascular and cerebrovascular diseases, and the incidence of the cardiovascular and cerebrovascular diseases can be reduced by curing the group, so the research is also carried out on the part of patients: setting a treatment group and a control group, wherein the treatment group is treated by using the pharmaceutical composition preparation of the invention, 5 granules at a time and twice a day; for the control group, 3-4 tablets were taken once, three times a day, for Xuesaitong (Terana); the medicine taking time of the treatment group and the control group is 100 days; the medicine is effective for eliminating symptoms after being taken for two weeks, but the effective rate is not a main item influencing the morbidity, so the symptom disappearance is recorded as: after stopping taking the medicine, observing that the disease does not relapse for 3 months and is clinically cured; clinical cure is the meaningful content of the study: patients with ages between 28 and 55 years, regardless of male and female, were instructed on treatment methods according to the order of visits, with freedom to choose which treatment method (divided into different groups) to use; the treatment group is selected from 46 patients, 38 patients are cured clinically, and the clinical cure rate is 82.6%; control group treatment of 21 persons; 9 cases of clinical cure, the clinical cure rate is 42.9 percent
Statistical table of treatment conditions of pharmaceutical composition preparation (treatment group) and Xuesaitong (control group) of the invention
p is less than 0.05, which indicates that the treatment group has obvious effect
From the above cases, the following clinical meanings are explained:
the case according to 61(1) may be considered that the pharmaceutical combination preparation of the present invention is expected to treat patients about one year or more after the disease.
The cases according to 62(2) show that the pharmaceutical composition preparation of the invention should be the best therapeutic agent when the hospital treatment in the early stage of cerebral apoplexy is ineffective, and can be used alone or combined with modern treatment methods.
The cases according to 63(3) should bring good news to patients suffering from coronary heart disease for a long time, especially patients suffering from severe decline of heart and constitution in the later stage of coronary heart disease have the hope of getting alive and getting alive, and can get back to the life of people with normal living post again.
According to 65 researches, the cerebral apoplexy sequela patients are considered to have the possibility of recovering the self-care function of life again, and the burden of families and society is reduced.
Studies according to 66 suggest elimination of symptoms and improvement in patient quality of life; and can reduce the disease recurrence rate of patients with cardiovascular and cerebrovascular diseases.
The study according to 67 suggests that symptoms will be eliminated, improving the quality of life of the patients; reduce the incidence of cardiovascular and cerebrovascular diseases.
Claims (10)
1. A specific Chinese medicinal composition for treating and preventing cardiovascular disease and cerebrovascular disease comprises BUYANGHUANWU decoction, semen Vaccariae, and cortex et radix Polygalae; the BUYANGHUANWU decoction comprises radix astragali, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, radix Paeoniae Rubra, Lumbricus, semen Persicae, and Carthami flos;
radix astragali, angelica, rhizoma ligustici wallichii, red peony root, earthworm, peach kernel, safflower, cowherb seed and polygala tenuifolia are prepared according to a certain proportion, and are concentrated and processed into pills, powder, tablets and capsules, namely Shenlingqiqiaohuotong capsules (pills, powder and tablets).
2. The Chinese medicinal composition preparation of claim 1, SHENLINGQIQIAOLUOTONG Capsule (pill, powder, tablet), for treating and preventing cardiovascular and cerebrovascular diseases such as coronary heart disease, angina pectoris diseases, cerebrovascular diseases such as apoplexy (cerebral apoplexy), and cerebral ischemia diseases; the special effect is that when the hospital treatment of 'cerebral apoplexy' is ineffective, the traditional Chinese medicine composition preparation can be used for further treatment, and can be used for curing, reducing the disability rate and improving the cure rate; secondly, all the medicine treatments in the later stage of coronary heart disease are ineffective, and when the patient is reluctant to live for self care, the patient can be restored to live as normal people by using the traditional Chinese medicine composition preparation; thirdly, related symptoms appear in the patients with cardiovascular and cerebrovascular diseases during the taking process, the disease condition is aggravated, and the possibility of relapse exists, so that the symptoms can be eliminated, the blood supply can be improved, and the relapse of the cardiovascular and cerebrovascular diseases can be avoided by taking the traditional Chinese medicine composition preparation; fourthly, the symptoms of relevant blood supply insufficiency are not diagnosed but appear, the cardiovascular and cerebrovascular diseases can be developed, and the symptoms and the blood supply insufficiency can be eliminated by taking the traditional Chinese medicine composition preparation, so that the morbidity is avoided; fifthly, the Chinese medicinal composition preparation can be taken twice a year to reduce blood viscosity and reduce the morbidity and the relapse of the cardiovascular and cerebrovascular diseases; sixthly, taking the medicine for a long time can strengthen the body and prolong the life.
3. The ratio of astragalus root, angelica, hemlock parsley, red peony root, earthworm, peach kernel, safflower, cowherb seed and polygala root in the Chinese medicinal composition preparation is 5: 1: 0.6: 0.4: 1: 0.8.
4. The Chinese medicinal composition according to claims 1 and 3, wherein the radix astragali in the Chinese medicinal composition is selected from radix astragali.
5. The Chinese medicinal composition according to claim 1 or 3, wherein the radix Angelicae sinensis in the Chinese medicinal composition is Angelica sinensis cauda, and can be replaced by Angelica sinensis without Angelica sinensis cauda.
6. The Chinese medicinal composition according to claim 1 or 3, wherein the earthworms in the Chinese medicinal composition are earthworms with soil removed, and most of the earthworms with soil slightly on both ends can be used if the earthworms with soil are not completely removed, but the earthworms with too much soil can never be used.
7. The Chinese medicinal composition according to claims 1 and 3, wherein the amount of the cowherb seed in the Chinese medicinal composition is half of the amount of raw cowherb seed and half of the amount of the fried cowherb seed, and the cowherb seed can be completely replaced by the amount of the fried cowherb seed if the raw cowherb seed is not present.
8. The Chinese medicinal composition according to claims 1 and 3, wherein the polygala root in the Chinese medicinal composition is core-pulling polygala root.
9. The processing method of the traditional Chinese medicine composition preparation for treating and preventing cardiovascular and cerebrovascular diseases of claim 1 is characterized in that:
firstly, the processing method of the traditional Chinese medicine composition preparation is a concentration pharmacy method with two overlapping drug effects;
the medicine curative effect is enhanced by a concentration pharmaceutical method with two overlapped medicine effects, the traditional Chinese medicine decoction pieces are rolled into medicine powder for standby, the effect of the traditional Chinese medicine decoction pieces is equal to that of a common Chinese patent medicine, the medicine effect is taken as one time, the same traditional Chinese medicine decoction pieces are decocted and concentrated, and the effective component is extracted to be the secondary medicine effect; the medicine powder with the first medicine effect is added into the concentrated solution with the second medicine effect and stirred into a whole, and the concentration processing and the two medicine effects are overlapped to increase the curative effect of the traditional Chinese medicine composite preparation.
The pharmaceutical process of the traditional Chinese medicine composition preparation comprises the following steps:
(1) preparing raw material powder, namely crushing traditional Chinese medicine decoction pieces according to the proportion of claim 3, selecting the traditional Chinese medicine decoction pieces according to the medicine standard of claims 4-8, and sieving the crushed traditional Chinese medicine decoction pieces with a sieve of 80-100 meshes to obtain fine medicine powder for later use as the raw material powder;
(2) decocting an initial liquid medicine, and then taking the traditional Chinese medicine decoction pieces according to the proportion of claim 3, the medicine decoction pieces selected according to the medicine standard of claims 4-8, wherein the weight ratio of the traditional Chinese medicine decoction pieces is as follows: soaking water in ml of tap water at a ratio of 1: 1.5 for half an hour, decocting at 100-125 deg.C for 50-60 min, pouring out the medicinal liquid, removing residues, filtering, and decocting for four times to obtain the initial medicinal liquid.
(3) And (3) concentrating, namely decocting the initial liquid medicine obtained in the step (2) at the temperature of 70-125 ℃ for about 10-12 hours to obtain 50% concentrated slurry.
(4) Shaping and drying, namely uniformly stirring the concentrated serous fluid liquid decocted in the step (3) according to the ratio of serous fluid ml to original drug powder g of about 2: 1, processing into small blocks and drying in the air.
(5) Rolling fine powder, rolling the dried medicine in the step (4) into fine powder, sieving the fine powder by a 100-mesh sieve to obtain pure fine powder for later use,
(6) and (4) finally forming, namely processing the pure fine powder prepared in the step (5) into pills, powder, tablets and capsules according to the requirements of patients.
10. The traditional Chinese medicine composition preparation is simple to take, convenient to carry and obvious in curative effect, and avoids the bad taste of traditional Chinese medicine decoction and the complexity of decoction; it can be administered at early stage, middle stage and late stage of cardiovascular and cerebrovascular diseases without the need of differentiation of symptoms and signs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010972171.6A CN113350404A (en) | 2020-09-16 | 2020-09-16 | Specific Chinese medicinal composition preparation for treating and preventing cardiovascular and cerebrovascular diseases and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010972171.6A CN113350404A (en) | 2020-09-16 | 2020-09-16 | Specific Chinese medicinal composition preparation for treating and preventing cardiovascular and cerebrovascular diseases and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113350404A true CN113350404A (en) | 2021-09-07 |
Family
ID=77524460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010972171.6A Pending CN113350404A (en) | 2020-09-16 | 2020-09-16 | Specific Chinese medicinal composition preparation for treating and preventing cardiovascular and cerebrovascular diseases and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113350404A (en) |
-
2020
- 2020-09-16 CN CN202010972171.6A patent/CN113350404A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101991816B (en) | Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases | |
| CN104606513B (en) | A kind of Chinese medicine for treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN101474361B (en) | Chinese medicine for treating cerebropathy | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN1994411A (en) | Medicine for treating cerebral apoplexy | |
| CN1977899B (en) | Medicine for treating rheumatoid arthritis | |
| CN102872455B (en) | Medicament for preventing in-stent restenosis after coronary stent implantation and preparation method | |
| CN102274396B (en) | Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof | |
| CN101843843A (en) | Chinese medicament for treating diabetes | |
| CN113350404A (en) | Specific Chinese medicinal composition preparation for treating and preventing cardiovascular and cerebrovascular diseases and application thereof | |
| CN104324134B (en) | One kind improves microcirculatory Chinese medicine composition and preparation method thereof | |
| CN102670718A (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method of same | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN101176743B (en) | Chinese medicine for curing coronary disease angina pectoris | |
| CN110339323A (en) | A kind of Chinese medicine composition and its preparation method and application for treating bradycardia | |
| CN108403983A (en) | Treat the stagnation resolvation Cyclandelate of cerebral infarction sequela | |
| CN113679781B (en) | Traditional Chinese medicine composition for treating tachyarrhythmia and preparation method and application thereof | |
| CN114796420B (en) | Traditional Chinese medicine composition for treating non-valvular atrial fibrillation as well as traditional Chinese medicine preparation and application thereof | |
| CN107961342A (en) | A kind of Chinese medicine composition for treating hemiplegia and preparation method thereof | |
| CN101953991B (en) | Medicine used for curing chronic cardiac insufficiency and preparation method thereof | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN105168653A (en) | Traditional Chinese medicine composition used for treating coronary heart disease | |
| CN101396424B (en) | Medicine composition for treating and preventing the cardio-cerebrovascular disease and preparation method thereof | |
| CN105055852A (en) | Chinese medicinal prescription for treatment of high blood pressure | |
| CN104958504A (en) | Traditional Chinese medicine composition for preventing and treating sub-health and preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |